Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study-Reference-Cited by-同舟云学术

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study

Published:2022-03 Issue:3 Volume:23 Page:416-427
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Richardson Paul G,Perrot Aurore,San-Miguel Jesus,Beksac Meral,Spicka Ivan,Leleu Xavier,Schjesvold Fredrik,Moreau Philippe,Dimopoulos Meletios A,Huang Jeffrey Shang-Yi,Minarik Jiri,Cavo Michele,Prince H Miles,Malinge Laure,Dubin Franck,van de Velde Helgi,Anderson Kenneth C

Publisher

Elsevier BV

Subject

Oncology

Reference22 articles.

1. Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide;Moreau;Blood Cancer J,2019

2. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study;Kumar;Leukemia,2012

3. CD38 antibodies in multiple myeloma: back to the future;van de Donk;Blood,2018

4. Identification of the enzymatic active site of CD38 by site-directed mutagenesis;Munshi;J Biol Chem,2000

5. Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology;Malavasi;Physiol Rev,2008

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trial;Blood Cancer Journal;2024-09-11

2. Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm;Blood Cancer Journal;2024-08-12

3. Pomalidomide/Daratumumab/Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Overall Survival From MM-014;Clinical Lymphoma Myeloma and Leukemia;2024-08

4. Targeting Ikaros and Aiolos: reviewing novel protein degraders for the treatment of multiple myeloma, with a focus on iberdomide and mezigdomide;Expert Review of Hematology;2024-07-27

5. Enhancing acute inflammatory and sepsis treatment: superiority of membrane receptor blockade;Frontiers in Immunology;2024-07-16